Language
English
Publication Date
8-1-2024
Journal
Arthritis & Rheumatology
DOI
10.1002/art.42861
PMID
38978310
Abstract
Objective: We provide evidence-based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs).
Methods: We developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A panel of clinicians and patients reached consensus on the direction and strength of the recommendations.
Results: Thirty-five recommendations were generated (including two strong recommendations) for first-line SARD-ILD treatment, treatment of SARD-ILD progression despite first-line ILD therapy, and treatment of rapidly progressive ILD. The strong recommendations were against using glucocorticoids in systemic sclerosis-ILD as a first-line ILD therapy and after ILD progression. Otherwise, glucocorticoids are conditionally recommended for first-line ILD treatment in all other SARDs.
Conclusion: This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the treatment of ILD in people with SARDs.
Keywords
Humans, Autoimmune Diseases, Disease Progression, Glucocorticoids, Lung Diseases, Interstitial, Rheumatic Diseases, Rheumatology, Scleroderma, Systemic, Societies, Medical, United States
Published Open-Access
yes
Recommended Citation
Johnson, Sindhu R; Bernstein, Elana J; Bolster, Marcy B; et al., "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases" (2024). Faculty and Staff Publications. 4189.
https://digitalcommons.library.tmc.edu/baylor_docs/4189